Eone Diagnomics Genome Center

What Eone Diagnomics Genome Center does

EDGC is a South Korea-based genomics and precision medicine company founded in 2013 as a joint venture between the Leewon Life Science Foundation and US-based Diagnomics Inc. The company specializes in cell-free DNA (cfDNA) analysis using next-generation sequencing (NGS) combined with proprietary bioinformatics, with operations spanning clinical diagnostics (non-invasive prenatal testing, newborn screening, liquid biopsy, cancer risk prediction, epigenetic aging), direct-to-consumer genomics (ancestry, wellness tracking), and drug development research. Listed on KOSDAQ since June 2018, EDGC serves expecting mothers, newborns, cancer patients, health-conscious consumers, and hospitals through a hybrid B2B/B2C model combining medical institution referrals, exclusive international distribution partners, and online DTC channels across more than 40 countries.

The company's technology stack centers on proprietary methylation analysis using restriction enzymes (OncoCatch), a DeepClean sequencing error-correction algorithm based on unique molecular barcodes, 2-stage Z-Score statistical methods for NIPT, and AI-driven multi-omics integration. EDGC holds CLIA certification in both Korea and the United States, was Korea's first Illumina analysis partner, and has accumulated over 500,000 clinical test data points used to train AI biomarkers and diagnostic algorithms. Core clinical products include TheMomScanning/NICE NIPT (Korea market leader with 99.9% detection rate), OncoCatch liquid biopsy (published AUC 0.978 for colorectal cancer and 0.956 for lung cancer in Scientific Reports), Gscanning/bebegene newborn screening, gene2me Plus disease risk panels, and the recently launched Epi-Clock epigenetic age measurement service participating in the $101M XPRIZE Healthspan competition. Consumer-facing offerings include YouWho (DTC ancestry), Uriwell (smart urine wellness tracker), and Yougenity (blockchain-based AI genome social network with GeniBot chatbot).

EDGC generates revenue primarily through per-test transaction fees from clinical genetic testing ordered through hospitals and clinics (the dominant historical revenue stream), supplemented by DTC consumer testing, licensing/royalty arrangements with international partners in 40+ countries, and Test Send Out (TSO) sample analysis for overseas clients. The company also derives professional services revenue through drug development collaborations (e.g., Virocute oncorovirus research). Revenue mix has been dominated by clinical NIPT historically, but management is actively diversifying into liquid biopsy (OncoCatch-E/S/CDx/M), epigenetics (Epi-Clock), AI-driven consumer platforms (Yougenity, GeniBot), and pharmaceuticals through its New Drug Development Research Institute.

Name

Eone Diagnomics Genome Center

Legal name

이원다이애그노믹스(주) / Eone Diagnomics Genome Center Co., Ltd.

Website

https://edgc.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

EDGC is a South Korean KOSDAQ-listed genomics company providing cfDNA-based clinical diagnostics (NIPT, liquid biopsy, newborn screening, epigenetic aging) and DTC consumer genomics (ancestry, wellness) across 40+ countries.

Ownership category

akta.pro rank

Product category

Clinical Genomics and Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling) (HLALAHAK), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Clinical genomic diagnostics
• Liquid biopsy testing
• Noninvasive prenatal screening
• Next generation sequencing
• Consumer ancestry testing

Headquarters

HQ city

Incheon

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Genetic Testing Services (B2B): EDGC provides prenatal (TheMomScanning/NICE), newborn (Gscanning/bebegene), liquid biopsy (OncoCatch), and cancer/genetic disease prediction (gene2me Plus, MyEyeGene) tests through medical institutions. Revenue is generated per test conducted via hospital/clinic referrals. Dominant revenue driver historically.
2. Consumer Genetic Testing (YouWho / DTC): Direct-to-consumer ancestry and genetic analysis service (YouWho). Consumer purchases test kit directly, submits saliva sample, receives online results. Premium memberships targeted for ongoing engagement.
3. Licensing & Royalties: EDGC earns licensing and royalty revenue from international distributors and partners using its proprietary cfDNA/NGS technologies in 40+ countries. Regional partners pay for technology access and service rights.
4. International Clinical Sample Testing (TSO): Test Send Out model: overseas patient samples are analyzed at EDGC Korean labs, with results delivered online to local hospitals. Revenue per sample analyzed for international clients.
5. Drug Development & Research Services: EDGC's new drug development research institute conducts cancer drug candidate research, generating revenue through research collaborations and partnerships with pharmaceutical companies (e.g., Virocute oncorovirus drug development, collaboration with Yonsei University).

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

EDGC is a clinical genomics company that develops and delivers DNA-based diagnostic testing services built on next-generation sequencing (NGS) and proprietary bioinformatics. Its core clinical services are non-invasive prenatal testing (TheMomScanning/NICE), newborn genome screening (Gscanning/bebegene), liquid biopsy for early cancer detection and monitoring (OncoCatch), and targeted disease-risk genetic panels (gene2me Plus, MyEyeGene), executed through referring hospitals and clinics. It also sells direct-to-consumer products such as the YouWho ancestry test, Epi-Clock epigenetic age test, and the Uriwell home wellness kit.

Product overview

EDGC operates as a diversified genomics healthcare platform offering clinical diagnostic tests, consumer genomics services, and AI-driven health platforms. The core clinical genomics portfolio includes TheMomScanning® (NIPT/prenatal screening), Gscanning® (neonatal genome screening), OncoCatch (liquid biopsy with four pipelines — E, S, CDx, M), gene2me® Plus (cancer and disease risk prediction), MyEyeGene® (ophthalmic genetics), TELOMERE® (cellular health), and Epi-Clock (epigenetic aging). Consumer-facing services include YouWho (genetic ancestry) and Uriwell (smart wellness tracker). Technology platforms encompass Yougenity (AI-powered genome social network), GeniBot (generative AI chatbot), EDGC Annotator (genomic variant annotation on BaseSpace), EpiCatch (epigenomics biomarker system), and GeniCode (blockchain genomic identity). The company also develops new drugs targeting cancer and operates clinical laboratory services across 40+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• TheMomScanning® / 더맘스캐닝: Non-invasive prenatal testing (NIPT) service for fetal chromosomal abnormalities using cfDNA analysis.
• Gscanning® / 지스캐닝
• NICE® / 나이스
• bebegene® / 베베진
• OncoCatch / 온코캐치
• Epi-Clock / 에피클락
• YouWho / 유후
• gene2me® Plus / 진투미플러스
• MyEyeGene® / 마이아이진
• TELOMERE® / 텔로미어
• MYGENPLAN® / 마이젠플랜
• Yougenity / 유젠이티
• GeniBot / 지니봇
• Uriwell / 유리웰
• EDGC Annotator
• OncoCatch cfDNA Tube
• EpiCatch / 에피캐치
• GeniCode / 지니코드

Products and services

• TheMomScanning® / NICE® Non-Invasive Prenatal Test Non-invasive prenatal testing (NIPT) service that analyzes fetal DNA from maternal blood using next-generation sequencing to screen for chromosomal abnormalities (Down, Edwards, and Patau syndromes) and fetal sex. Available from 10 weeks for singletons and 12 weeks for twins. Marketed internationally as NICE® and domestically as TheMomScanning®.
• Gscanning® / bebegene® Newborn Genome Screening

Quantifiable outcome

• NIPT detection rate of 99.9% (singleton from 10 weeks, twins from 12 weeks)
• +4 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability9 records

Feature10 records

Partnerships

25 partnerships are on record, tiered core, strategic and minor.

• XPRIZE FoundationcoreStrategic or Co-development Partner · 26 February 2024EDGC participating in XPRIZE Healthspan competition (team name: Epi-Clock) with $101M prize for reversing aging by 20+ years. EDGC developing methylation-based biological age measurement assay system for longevity research.
• Ewha Womans University Seoul HospitalstrategicStrategic or Co-development Partner · 27 September 2021MOU for precision medicine innovation with EDGC providing genomic analysis capabilities and the hospital providing clinical research infrastructure.
• E-LandstrategicStrategic or Co-development Partner · 11 August 2021Development agreement for genome convergence data healthcare platform combining EDGC's genomic data with E-Land's retail and consumer platform capabilities.
• North American nutraceutical manufacturerstrategicChannel Partner/ Reseller/ Distributor · 19 July 2021EDGC acquired North American nutraceutical manufacturer to secure steady cash flow and expand into the health supplements market.
• K-DNA Consortium (ClinoMics, Medigen Human Care, LabGenomics, CancerRop)strategicStrategic or Co-development Partner · 5 August 2020K-DNA consortium of 5 genomics companies including EDGC competing for government K-DNA project (100,000 genome, 1.5 trillion KRW over 10 years).
• Gangnam Major Hospital / CheonLab / BeLink HealthcarestrategicStrategic or Co-development Partner · 9 March 202010,000-genome project partnership for genetic disease prediction research. EDGC responsible for genome analysis and database construction. Combining genomic data with microbiome analysis and health examination data for disease prediction models.
• Capital Medical University (China) and Fudan University Cancer Hospital (China)strategicStrategic or Co-development Partner · 10 January 2020Joint research agreement for liquid biopsy development targeting NMPA regulatory approval. Capital Medical University provides medical facilities and professionals; Fudan Cancer Hospital brings genomics expertise. Goal to launch liquid biopsy service in China by end of 2020.
• Hewlett Packard Enterprise (HPE)strategicTechnology or Integration · 22 November 2019EDGC collaborated with HPE at SC19 conference to present liquid biopsy research results. HPE HPC demonstrated 16-54% time reduction in liquid biopsy data analysis compared to standard servers. Collaboration for accelerating liquid biopsy commercialization through high-performance computing.
• Samsung Seoul Hospital / Seoul National University / Korea University / Soonchunhyang University Bucheon HospitalcoreStrategic or Co-development Partner · 14 November 2019EDGC selected as performer in Ministry of Health and Welfare's 'PREMIER Consortium' (3-year, 9 billion KRW project) for precision medicine platform for mild cognitive impairment dementia. EDGC developing epigenetic/genomic early diagnosis kit.
• IlluminacoreTechnology or Integration · 21 October 2019EDGC is Korea's first and only Illumina analysis partner. Developed EDGC Annotator genomic annotation tool, available free on BaseSpace Appstore. Illustmina invited EDGC to present at Illumina Summit 2019, recognizing EDGC as a notable DTC company.
• MH (Germany)strategicChannel Partner/ Reseller/ Distributor · 15 September 2019EDGC signed joint marketing agreement with German company MH for OncoCatch liquid biopsy to capture European market share.
• Sookmyung Women's UniversityminorStrategic or Co-development Partner · 2 July 2019MOU for cultivating next-generation genomic specialists through academic-industry partnership.
• UMH (Union Medical Healthcare) / New Town Medical GroupstrategicChannel Partner/ Reseller/ Distributor · 5 June 2019OncoCatch liquid biopsy service supply agreements with UMH and New Town Medical Group for Asian market.
• GBI (China)strategicChannel Partner/ Reseller/ Distributor · 30 May 2019GBI partnership for pet genomics market entry in China, combining EDGC's genomic technology with GBI's local market access.
• Loi&Ray (China)strategicStrategic or Co-development Partner · 17 May 2019Partnership with Loi&Ray for genomic cosmetics development targeting the Chinese market.
• VirocutestrategicStrategic or Co-development Partner · 23 April 2019Collaboration with Virocute on oncolytic virus drug development using EDGC's genomic analysis capabilities. Virocute's improved oncolytic virus platform selected for Canadian government COVID-19 vaccine project.
• Gangnam Mizmedi HospitalstrategicStrategic or Co-development Partner · 3 April 2019Strategic research collaboration for precision medicine using genomic big data at Gangnam Mizmedi Hospital.
• SCG (Thailand)strategicStrategic or Co-development Partner · 11 February 2019MOU for medical cannabis R&D collaboration, exploring genomic applications in medical cannabis research.
• CNS HealthcarestrategicChannel Partner/ Reseller/ Distributor · 4 September 2018EDGC acquired CNS Healthcare to expand quality and quantitative growth in the genomics and healthcare market.
• EDGC Hong Kong SubsidiarycoreChannel Partner/ Reseller/ Distributor · 13 July 2018EDGC Hong Kong subsidiary established for Greater China market expansion and operations.
• OncoDNAcoreTechnology or Integration · 5 August 2015EDGC holds exclusive sales rights for OncoDEEP DX panel and OncoShare web platform in Korea, enabling clinical analysis of cancer genetic test results using Ion Torrent-based NGS technology analyzing 50+ genes.
• EW Medical Foundation (이원의료재단)coreStrategic or Co-development Partner · 17 July 2013EDGC established through joint venture between Korean EW Medical Foundation and US-based Diagnomics (San Diego). EW Medical Foundation provides clinical expertise and research capabilities for molecular diagnostics development.
• SYNLAB (Germany)coreChannel Partner/ Reseller/ DistributorSYNLAB (€19B annual revenue, 5 billion+ tests/year, 42 subsidiaries in 34 European countries + Middle East + Latin America) signed €2M supply contract for EDGC/Solgent COVID-19 diagnostic kits. Ongoing strategic partnership for European market expansion.
• NGENI (US)strategicTechnology or IntegrationUS-based research institute collaborating with EDGC on GeniCode (Genome Decentralized Identification) digital identity system, classifying genetic information into 24 codes.
• Korea Polar Research InstituteminorStrategic or Co-development PartnerPartnership to provide COVID-19 diagnostic kits and testing equipment for Antarctic and Korean polar research stations.

Scale indicators9 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• 23andMe: 23andMe is the pioneer of direct-to-consumer genetic testing (ancestry, health risk) — directly comparable to EDGC's YouWho DTC ancestry service and broader consumer genomics strategy. Both face similar regulatory, data privacy, and consumer demand dynamics in the DTC category.
• Guardant Health: Guardant Health is the US liquid biopsy leader (Guardant360 CDx, Shield CRC screening), directly comparable to EDGC's OncoCatch-E early cancer detection and OncoCatch-CDx companion diagnostic pipelines. Both target oncology detection and monitoring via cfDNA analysis with proprietary methylation/molecular methods.
• BGI Genomics: BGI Genomics is the China-based NIPT and genetic testing leader (NIFTY) — directly comparable to EDGC's NICE NIPT business. Both serve the global NIPT market via TSO/cross-border lab models and operate extensive hospital-channel distribution networks in Asia, Europe, and emerging markets.
• Natera: Natera is a US-based genetic testing company with leading NIPT (Panorama) and oncology liquid biopsy (Signatera) franchises — directly comparable to EDGC's NIPT (NICE/TheMomScanning) and OncoCatch-M recurrence monitoring pipelines. Both compete for the same hospital and lab channels globally.
• Berry Genomics: Berry Genomics is a China-based NIPT and rare disease diagnostics provider — directly comparable to EDGC's NIPT franchise and newborn genetic screening (Gscanning). Both target prenatal and pediatric chromosomal testing in Asian and emerging markets.
• Myriad Genetics: Myriad Genetics is a US-based genetic testing leader in hereditary cancer (BRACAnalysis), prenatal testing, and oncology — directly comparable to EDGC's gene2me Plus cancer risk testing, MyEyeGene, and broader clinical genetic testing portfolio. Both monetize hospital-channel hereditary disease testing.
• NeoGenomics: NeoGenomics is a US-based oncology-focused clinical laboratory offering solid tumor profiling, liquid biopsy, and hematologic testing — directly comparable to EDGC's OncoCatch CDx companion diagnostics pipeline. Both serve oncologists and pharma CDx partnerships.
• Exact Sciences: Exact Sciences is a US-based cancer screening and diagnostics company (Cologuard, Oncotype DX, Oncodetect MRD) — directly comparable to EDGC's OncoCatch-E colorectal/lung cancer screening pipeline and broader liquid biopsy ambitions. Both pursue non-invasive cancer detection in blood.

Broad incumbents

• Illumina: Illumina is the global sequencing platform incumbent and EDGC's first Korean analysis partner (BaseSpace EDGC Annotator integration). As the dominant NGS instrumentation and reagent provider, Illumina is both an enabler (technology platform) and a potential vertical competitor through its own NIPT/liquid biopsy initiatives.

Regional players

• Macrogen: Macrogen is a Korean-headquartered genomic analysis service provider (DNA sequencing, clinical genomics, precision medicine) — directly comparable to EDGC's clinical genomics services within Korea. Both compete for Korean hospital and research institution sequencing contracts in the domestic market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCt5aVJFgklynWKFCi8qFKCQ
• Facebookfacebook.com/edgc.official

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eone Diagnomics Genome Center